ant Attorney General and shall be published in the FEDERAL REGISTER.

(b) Where such designations or delegations of functions have been made, the agencies shall adopt adequate written procedures to assure that the same standards of compliance with Title VI are utilized at the operational levels by each of the agencies. This may include notification to agency personnel in handbooks, or instructions on any forms used regarding the compliance procedures.

(c) Any agency conducting a compliance review or investigating a complaint of an alleged Title VI violation shall notify any other affected agency upon discovery of its jurisdiction and shall subsequently inform it of the findings made. Such reviews or investigations may be made on a joint basis.

(d) Where a compliance review or complaint investigation under Title VI reveals a possible violation of Executive Order 11246, Title VII of the Civil Rights Act of 1964 (42 U.S.C. 2000e), or any other federal law, the appropriate agency shall be notified.

§ 42.414 Federal agency staff.

Sufficient personnel shall be assigned by a federal agency to its Title VI compliance program to ensure effective enforcement of Title VI.

§ 42.415 Federal agency Title VI enforcement plan.

Each federal agency subject to Title VI shall develop a written plan for enforcement which sets out its priorities and procedures. This plan shall be available to the public and shall address matters such as the method for selecting recipients for compliance reviews, the establishment of timetables and controls for such reviews, the procedure for handling complaints, the allocation of its staff to different compliance functions, the development of guidelines, the determination as to when guidelines are not appropriate, and the provision of civil rights training for its staff.

Effective date: This subpart shall become effective thirty days after final publication in the FEDERAL REGISTER.

[FR Doc.76-21990 Filed 7-28-76;8:45 am]

Drug Enforcement Administration

[21 CFR Part 1308]

HALAZEPAM, PRAZEPAM AND LOPERAMIDE

Proposed Placement in Schedules IV and V

On January 23, 1976, the Assistant Secretary for Health, on behalf of the Secretary of Health, Education, and Welfare sent a letter to the then-Acting Administrator of the Drug Enforcement Administration which recommended that several drugs be placed into or removed from certain schedules of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 801–966). Among the drugs recommended for placement into schedules were halazepam, prazepam and loperamide. Halazepam and prazepam were recommended for Schedule IV, and loperamide was recommended for Schedule V.

Enclosed with the letter from the Assistant Secretary was a document which listed, for each recommended drug, the factors which the Act requires the Secretary to consider and the summarized considerations of the Secretary in recommending control or decontrol action for the subject drugs.

The factors considered by the Secretary for halazepam, prazepam and loperamide were, for each:

1. Its actual or relative potential for abuse.
2. Scientific evidence of its pharmacologic effect, if known.
3. The state of current scientific knowledge regarding the drug or other substance.
4. Its history and current pattern of abuse.
5. The scope, duration, and significance of abuse.
6. What, if any, risk there is to the public health.
7. Its psychic or physiological dependence liability.
8. Whether the substance is an immediate precursor of a substance already controlled under the Controlled Substances Act.

The Administrator, in reliance upon the evaluations and recommendations of the Secretary transmitted to the Administrator in the letter and enclosure of the Assistant Secretary for Health, hereby gives notice that he accepts the control recommendations of the Secretary of Health, Education, and Welfare that halazepam and prazepam be placed into Schedule IV and that loperamide be placed into Schedule V of the Act.

Therefore, and pursuant to the authority vested in the Attorney General by section 201(a) of the Act (21 U.S.C. 811 (a)), and delegated to the Administrator of the Drug Enforcement Administration by regulations of the Department of Justice (28 CFR Part O), the Administrator hereby proposes that 21 CFR 1308.14(b) and 1308.15 be amended as follows:

§ 1308.14 Schedule IV.

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned by the DEA Controlled Substances Code Number set forth opposite it.

(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

* * * * *

(11)	Halazepam	2762
(12)	Mebutamate	2800
(13)	Meprobamate	2820
(14)	Methohexital	2264
(15)	Methylphenobarbital	2250
(16)	Oxazepam	2835
(17)	Paraldehyde	2585
(18)	Petrichloral	2591
(19)	Phenobarbital	2285
(20)	Prazepam	2764

* * * * *

§ 1308.15 Schedule V.

(a) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

* * * * *

(c)	Loperamide	8125

* * * * *

All interested persons are invited to submit their comments or objections in writing regarding these proposals. These comments or objections should state with particularity the issues concerning which the person desires to be heard. Comments and objections should be submitted in quintuplicate to the Administrator, Drug Enforcement Administration, United States Department of Justice, 1405 Eye Street, N.W., Washington, D.C. 20537, Attention: DEA Federal Register Representative, and must be received on or before August 31, 1976.

In the event that an interested party submits objections to these proposals which present reasonable grounds for these rules not to be finalized and requests a hearing in accordance with 21 CFR 1308.45, the party will be notified by registered mail of the time and place that the hearing will be held. If any objections which are submitted do not present reasonable grounds, the party will be so advised by registered mail.

If no objections presenting grounds for a hearing on these proposals are received within the time limitations, or all interested parties waive or are deemed to waive their opportunity for a hearing or to participate in a hearing, the Administrator, after giving consideration to written comments and objections, will issue his final orders pursuant to 21 CFR 1308.48 without a hearing.

Dated: July 26, 1976.

PETER B. BENSINGER,
Administrator,
Drug Enforcement Administration.

[FR Doc.76-22041 Filed 7-28-76;8:45 am]

DEPARTMENT OF THE INTERIOR

Mining Enforcement and Safety Administration

[30 CFR Part 75]

UNDERGROUND COAL MINES

Proposed Mandatory Safety Standards

Notice is hereby given that in accordance with the provisions of section 101 of the Federal Coal Mine Health and Safety Act of 1969 (Pub. L. 91–173, 83 Stat. 742, 30 U.S.C. 801) and pursuant to the authority vested in the Secretary of the Interior under section 101(a) of the Act, it is proposed that Part 75, Subchapter O, Chapter I, Title 30, Code of Federal Regulations be amended by adding a new Subpart T—Training and Retraining of Miners, as set forth below.

The new Subpart T will require coal mine operators to adopt programs for the training of inexperienced miners, training of experienced miners, training of miners for new work assignments, and annual training of miners. The proposed standards prescribe the courses of in-